Incidence, characteristics and outcomes in patients with embolic stroke of undetermined source: A population-based study

Embolic stroke of undetermined source (ESUS) represents a subgroup of cryptogenic ischemic stroke (CS) distinguished by high probability of an underlying embolic mechanism. There are scarce population-based data regarding the incidence, characteristics and outcomes of ESUS. Consecutive patients incl...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of the neurological sciences 2019-06, Vol.401, p.5-11
Hauptverfasser: Tsivgoulis, Georgios, Kargiotis, Odysseas, Katsanos, Aristeidis H., Patousi, Athanasia, Mavridis, Dimitris, Tsokani, Sofia, Pikilidou, Maria, Birbilis, Theodosis, Mantatzis, Michael, Zompola, Christina, Triantafyllou, Sokratis, Papanas, Nikolaos, Skendros, Panagiotis, Terzoudi, Aikaterini, Georgiadis, George S., Maltezos, Efstratios, Piperidou, Charitomeni, Tsioufis, Konstantinos, Heliopoulos, Ioannis, Vadikolias, Konstantinos
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Embolic stroke of undetermined source (ESUS) represents a subgroup of cryptogenic ischemic stroke (CS) distinguished by high probability of an underlying embolic mechanism. There are scarce population-based data regarding the incidence, characteristics and outcomes of ESUS. Consecutive patients included with first-ever ischemic stroke of undetermined cause in the previously published population-based Evros Stroke Registry were further subdivided into ESUS and non-ESUS CS. Crude and adjusted [according to the European Standard Population (ESP), WHO and Segi population] incidence rates (IR) for ESUS and non-ESUS CS were calculated. Baseline characteristics, admission stroke severity (assessed using NIHSS-score), stroke recurrence and functional outcomes [determined by modified Rankin Scale (mRS) scores], were recorded during the 1-year follow-up period. We identified 21 and 242 cases with ESUS (8% of CS) and non-ESUS CS. The crude and ESP-adjusted IR for ESUS were 17.5 (95%CI: 10–25) and 16.6 (95%CI: 10–24) per 100,000 person-years. Patients with ESUS were younger (p 
ISSN:0022-510X
1878-5883
DOI:10.1016/j.jns.2019.04.008